FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3142959462> ?p ?o ?g. }

• W3142959462 endingPage "e196" @default.
• W3142959462 startingPage "e185" @default.
• W3142959462 abstract "Background There is a need for more convenient, less frequent treatment to help address challenges associated with daily oral HIV treatment in people living with HIV, including stigma, pill burden, drug–food interactions, and adherence. The phase 3 ATLAS and FLAIR studies showed non-inferiority of long-acting cabotegravir and rilpivirine dosed every 4 weeks compared with standard oral therapy for the maintenance of virological suppression in adults with HIV-1 over 48 weeks. We present the 96-week findings. Methods FLAIR is a randomised, phase 3, open-label, multicentre study done in 11 countries investigating whether switching to long-acting cabotegravir and rilpivirine is non-inferior to daily dolutegravir, abacavir, and lamivudine in virologically suppressed adults living with HIV-1. Antiretroviral therapy (ART)-naive participants received induction therapy with daily oral dolutegravir (50 mg), abacavir (600 mg), and lamivudine (300 mg) for 20 weeks. After 16 weeks, participants with less than 50 HIV-1 RNA copies per mL were randomly assigned (1:1) to continue the standard of care regimen (standard care group) or switch to receive daily oral cabotegravir 30 mg and rilpivirine 25 mg for at least 4 weeks followed by long-acting cabotegravir 400 mg and rilpivirine 600 mg, administered as two 2 mL intramuscular injections, every 4 weeks for at least 96 weeks (long-acting group). Randomisation was stratified by baseline (preinduction) HIV-1 RNA (<100 000 or ≥100 000 copies per mL) and sex at birth and used GlaxoSmithKline-verified randomisation software (RandAll NG, version 1.3.3) for treatment assignment. The primary endpoint was the proportion of participants with plasma HIV-1 RNA of 50 copies per mL or more assessed as per the US Food and Drug Administration (FDA) Snapshot algorithm at week 48, which has been reported previously. Here, we report the proportion of participants with 50 or more HIV-1 RNA copies per mL using the FDA Snapshot algorithm at week 96 (intention-to-treat population; non-inferiority margin 6%). The trial is registered with ClinicalTrials.gov, NCT02938520. Findings Between Oct 27, 2016, and March 24, 2017, 809 participants were screened. 631 (78%) participants entered the induction phase and 566 (70%) were randomly assigned to either the standard care group (283 [50%] participants) or the long-acting group (283 [50%]). Median age was 34 years (IQR 29 to 43), 62 (11%) were 50 years or older, 127 (22%) were women (sex at birth), and 419 (74%) were white. At week 96, nine (3%) participants in each arm had 50 or more HIV-1 RNA copies per mL, with an adjusted difference of 0·0 (95% CI –2·9 to 2·9), consistent with non-inferiority established at week 48. Across both treatment groups, adverse events leading to withdrawal were infrequent (14 [5%] participants in the long-acting group and four [1%] in the standard care group). Injection site reactions were the most common adverse event, reported by 245 (88%) participants in the long-acting group; their frequency decreased over time. Median injection site reaction duration was 3 days (IQR 2 to 4), and 3082 (99%) of 3100 reactions were grade 1 or 2. No deaths occurred during the maintenance phase. Interpretation The 96-week results reaffirm the 48-week results, showing long-acting cabotegravir and rilpivirine continued to be non-inferior compared with continuing a standard care regimen in adults with HIV-1 for the maintenance of viral suppression. These results support the durability of long-acting cabotegravir and rilpivirine, over an almost 2-year-long period, as a therapeutic option for virally suppressed adults with HIV-1. Funding ViiV Healthcare and Janssen Research and Development." @default.
• W3142959462 created "2021-04-13" @default.
• W3142959462 creator A5004474608 @default.
• W3142959462 creator A5007250313 @default.
• W3142959462 creator A5009272615 @default.
• W3142959462 creator A5011202454 @default.
• W3142959462 creator A5013078758 @default.
• W3142959462 creator A5033022834 @default.
• W3142959462 creator A5033195921 @default.
• W3142959462 creator A5033324276 @default.
• W3142959462 creator A5034571044 @default.
• W3142959462 creator A5043793286 @default.
• W3142959462 creator A5044001938 @default.
• W3142959462 creator A5045218126 @default.
• W3142959462 creator A5046228013 @default.
• W3142959462 creator A5048320845 @default.
• W3142959462 creator A5050421096 @default.
• W3142959462 creator A5056946284 @default.
• W3142959462 creator A5057748120 @default.
• W3142959462 creator A5061678587 @default.
• W3142959462 creator A5061966779 @default.
• W3142959462 creator A5066658805 @default.
• W3142959462 creator A5072097342 @default.
• W3142959462 creator A5072331363 @default.
• W3142959462 creator A5072437068 @default.
• W3142959462 creator A5078051381 @default.
• W3142959462 creator A5079072445 @default.
• W3142959462 creator A5081694040 @default.
• W3142959462 creator A5085142733 @default.
• W3142959462 date "2021-04-01" @default.
• W3142959462 modified "2023-10-18" @default.
• W3142959462 title "Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study" @default.
• W3142959462 cites W1674196795 @default.
• W3142959462 cites W1990788636 @default.
• W3142959462 cites W2037635462 @default.
• W3142959462 cites W2075144974 @default.
• W3142959462 cites W2096981707 @default.
• W3142959462 cites W2137053633 @default.
• W3142959462 cites W2328594556 @default.
• W3142959462 cites W2738541296 @default.
• W3142959462 cites W2781681713 @default.
• W3142959462 cites W2899797830 @default.
• W3142959462 cites W2899935160 @default.
• W3142959462 cites W2935316344 @default.
• W3142959462 cites W2937692116 @default.
• W3142959462 cites W2979917028 @default.
• W3142959462 cites W2981457345 @default.
• W3142959462 cites W2982150070 @default.
• W3142959462 cites W3000709627 @default.
• W3142959462 cites W3009494891 @default.
• W3142959462 cites W3010513804 @default.
• W3142959462 cites W3082576563 @default.
• W3142959462 cites W3111050887 @default.
• W3142959462 cites W4292528167 @default.
• W3142959462 doi "https://doi.org/10.1016/s2352-3018(20)30340-4" @default.
• W3142959462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33794181" @default.
• W3142959462 hasPublicationYear "2021" @default.
• W3142959462 type Work @default.
• W3142959462 sameAs 3142959462 @default.
• W3142959462 citedByCount "62" @default.
• W3142959462 countsByYear W31429594622021 @default.
• W3142959462 countsByYear W31429594622022 @default.
• W3142959462 countsByYear W31429594622023 @default.
• W3142959462 crossrefType "journal-article" @default.
• W3142959462 hasAuthorship W3142959462A5004474608 @default.
• W3142959462 hasAuthorship W3142959462A5007250313 @default.
• W3142959462 hasAuthorship W3142959462A5009272615 @default.
• W3142959462 hasAuthorship W3142959462A5011202454 @default.
• W3142959462 hasAuthorship W3142959462A5013078758 @default.
• W3142959462 hasAuthorship W3142959462A5033022834 @default.
• W3142959462 hasAuthorship W3142959462A5033195921 @default.
• W3142959462 hasAuthorship W3142959462A5033324276 @default.
• W3142959462 hasAuthorship W3142959462A5034571044 @default.
• W3142959462 hasAuthorship W3142959462A5043793286 @default.
• W3142959462 hasAuthorship W3142959462A5044001938 @default.
• W3142959462 hasAuthorship W3142959462A5045218126 @default.
• W3142959462 hasAuthorship W3142959462A5046228013 @default.
• W3142959462 hasAuthorship W3142959462A5048320845 @default.
• W3142959462 hasAuthorship W3142959462A5050421096 @default.
• W3142959462 hasAuthorship W3142959462A5056946284 @default.
• W3142959462 hasAuthorship W3142959462A5057748120 @default.
• W3142959462 hasAuthorship W3142959462A5061678587 @default.
• W3142959462 hasAuthorship W3142959462A5061966779 @default.
• W3142959462 hasAuthorship W3142959462A5066658805 @default.
• W3142959462 hasAuthorship W3142959462A5072097342 @default.
• W3142959462 hasAuthorship W3142959462A5072331363 @default.
• W3142959462 hasAuthorship W3142959462A5072437068 @default.
• W3142959462 hasAuthorship W3142959462A5078051381 @default.
• W3142959462 hasAuthorship W3142959462A5079072445 @default.
• W3142959462 hasAuthorship W3142959462A5081694040 @default.
• W3142959462 hasAuthorship W3142959462A5085142733 @default.
• W3142959462 hasConcept C126322002 @default.
• W3142959462 hasConcept C142462285 @default.
• W3142959462 hasConcept C159047783 @default.
• W3142959462 hasConcept C197934379 @default.
• W3142959462 hasConcept C2522874641 @default.
• W3142959462 hasConcept C2777869810 @default.
• W3142959462 hasConcept C2778375690 @default.

• next